Evofem Biosciences, Inc.
EVFM
$0.01
$0.002.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.59% | 10.14% | 15.99% | -76.55% | 46.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.59% | 10.14% | 15.99% | -76.55% | 46.81% |
| Cost of Revenue | 71.43% | 4.14% | -1.82% | -46.64% | 58.49% |
| Gross Profit | 24.62% | 11.58% | 20.02% | -83.56% | 43.94% |
| SG&A Expenses | -43.81% | -17.56% | -0.93% | -3.95% | -4.32% |
| Depreciation & Amortization | -72.01% | -73.42% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.33% | -14.45% | 9.50% | -91.97% | -1.36% |
| Operating Income | 433.50% | 59.75% | 9.94% | 111.50% | 70.33% |
| Income Before Tax | 191.77% | 33.71% | -230.76% | 119.88% | -43.66% |
| Income Tax Expenses | -- | 50.00% | -12.50% | -- | -- |
| Earnings from Continuing Operations | 191.80% | 33.66% | -232.05% | 119.88% | -43.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 191.80% | 33.66% | -232.05% | 119.88% | -43.66% |
| EBIT | 433.50% | 59.75% | 9.94% | 111.50% | 70.33% |
| EBITDA | 605.74% | 57.90% | 17.51% | 119.63% | 79.75% |
| EPS Basic | 166.32% | 43.09% | -178.97% | 105.39% | 93.41% |
| Normalized Basic EPS | 166.48% | -27.08% | -175.59% | 104.46% | 84.20% |
| EPS Diluted | 100.69% | 43.09% | -2,600.00% | 100.13% | 96.04% |
| Normalized Diluted EPS | 100.56% | -27.08% | -2,020.00% | 100.08% | 84.20% |
| Average Basic Shares Outstanding | 37.96% | 23.97% | 73.25% | 263.39% | 807.32% |
| Average Diluted Shares Outstanding | 23,852.46% | 23.97% | -92.83% | 19,262.12% | 807.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |